Navigation Links
NewCardio to Showcase Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City on May 10, 2011
Date:5/2/2011

SANTA CLARA, Calif., May 2, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, today announced its selection for the prestigious NYC Bright Lights Conference at the Le Parker Meridien Hotel in New York City. Bright Lights is the only conference of its kind with an exclusive focus on publicly traded companies with disruptive and market changing intellectual property (IP). NewCardio will present on May 10, 2011 at 9 a.m. ET.

NewCardio was selected from MDB's 2011 group of "Best and Brightest" small-cap companies, a group that is advancing some of today's most innovative and market-leading intellectual property (IP). It is one of the 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by PatentVest, MDB's proprietary IP business intelligence platform.

Christopher Marlett, CEO at MDB Capital Group, comments, "It's a rare and exciting opportunity to have so many key players that are driving IP asset monetization together under one roof and we look forward to sharing NewCardio's cardiac diagnostic technology with other innovators and investors at the Bright Lights conference."

Bright Lights also features high-profile speakers including the top IP experts in the nation, such as David Kappos, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (USPTO), who will be joining as a keynote speaker; in addition to Marshall Phelps, former head of Microsoft IP, and John Cronin, former head of IBM's Patent Factory, and Paul Ryan of Acacia Research.

The second annual Bright Lights Conference will take place on May 10 - 11th at the Le Parker Meridien Hotel in New York City. To learn more about the event, please visit: http://www.mdb.com.  

Investors and other interested partie
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NewCardio Announces Positive Results From Third Clinical Validation Study
2. Vincent W. Renz Joins NewCardio as President
3. NewCardio Leadership to Present Two Abstracts at ISCE Conference
4. NewCardio Announces Master Services Agreement With Dedicated Phase I
5. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
6. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
7. NewCardio CEO Increases Equity Position
8. NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded Testing Dataset
9. NewCardio Announces Financial Results for Its 2010 Third Quarter
10. NewCardios Chief Technical Officer, Dr. Dorin Panescu, Named 2011 IEEE Fellow
11. NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  Hill-Rom Holdings, Inc. ... Stacy Enxing Seng has been elected to its ... Executive in Residence for Covidien, as well as President ... President of Peripheral Vascular from 2010 to 2012. ... the $2.6B acquisition of ev3 Incorporated, where she was ...
(Date:3/4/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... Phase II proof of concept clinical study investigating ... monotherapy in the treatment of chronic pruritus in ... and clinically meaningful improvement from baseline by tradipitant ... a 100mm unit Visual Analog Scale (VAS) for ...
(Date:3/4/2015)... NEW YORK , March 4, 2015 /PRNewswire/ ... orthopedic device market is the increasing elderly population, ... in a recent report from the healthcare market ... aging population coupled with other risk factors such ... orthopedic incidence worldwide. Demand for innovative product designs ...
Breaking Medicine Technology:Hill-Rom Elects Stacy Enxing Seng to its Board of Directors 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3
... , , , , ... Inc. (Nasdaq: RIGL ) today announced that in the ... had failed to respond to at least one biologic treatment, the ... ACR 20, ACR 50, ACR 70 and DAS28 response rates than ...
... , G rowth ... for cardiac stem cells , ... regrow, but researchers at Children,s Hospital Boston have now laid the groundwork for ... in children with congenital heart defects. In the July 24 issue of ...
Cached Medicine Technology:R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 2R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 3R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 4R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 5R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 6R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 7R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 8Injection Reverses Heart-Attack Damage 2Injection Reverses Heart-Attack Damage 3
(Date:3/4/2015)... Understanding China’s New Medical Device Regulations, **FDAnews ... p.m. EDT, http://www.fdanews.com/UnderstandingChinaMDRegs , There has been ... devices in China. , These new regulations touch ... development, approval, manufacturing, distribution, and post-market surveillance. And ... as well as those that are already on the ...
(Date:3/4/2015)... 2015 The emergence of nanotechnology ... the past decade. The pharmaceutical world has witnessed ... in the form of liposomes and polymeric nanoparticles ... more safety and efficiency. In the area ... greatly upon the enhanced permeability and retention (EPR) ...
(Date:3/4/2015)... Tenn. (PRWEB) March 04, 2015 Imagine No ... receive the Care2 Innovator Award , an honor given ... presented today at the Nonprofit Technology Conference (NTC15) ... of Tarrytown United Methodist Church in Austin, was on hand ... Committee for Imagine No Malaria. , Imagine No Malaria was ...
(Date:3/4/2015)... In the Ultimate Fighting Championship, each event is ... event. For UFC 189 , just one official fight ... UFC Featherweight Championship. Brazilian champion Jose “Junior” Aldo will defend ... Conor “Notorious” McGregor. UFC 189 will take place on July ... NV. , When it comes to the featherweight division in ...
(Date:3/4/2015)... The Asia-Pacific phthalic anhydride market is ... by 2019, at a CAGR of 5.9% during ... Browse through the TOC of Asia-Pacific Phthalic Anhydride ... segments, with the help of various tables and ... is a derivative of phthalic acid, which is ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 2Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 3Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:Imagine No Malaria Receives Care2 Innovator Award 2Health News:Imagine No Malaria Receives Care2 Innovator Award 3Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 3Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3
... a discovery that may well be giving HIV health care workers ... men having a highly drug resistant form of HIV in King ... rapidly than others and is likewise more difficult to treat. ... present in the four men, all gay, who are also methamphetamine ...
... the Intensive Care Unit (ICU) and family members of ... and depression in the family members, according to a ... of the New England Journal of Medicine. ... Institute of Nursing Research (NINR), a component of the ...
... impairment that strikes in the early stages of prion diseases such ... ,The findings suggest there may be a way to cure ... before it has time to kill off large numbers of brain ... lives of 158 people in Britain, and seven more are known ...
... women’s menstrual cycles affect the responsiveness of their brains’ ... of// Mental Health (NIMH), a component of the National ... ,While women were winning rewards, their circuitry was more ... ovulation and dominated by estrogen, compared to a phase ...
... genes from an ancient wheat variety have led to a ... a recent set of papers published in the journal Plant ... and Nax2. The genes work by excluding salt from different ... from the leaves. The discovery of the two genes is ...
... grant product patent for Glivec, the cancer drug from Novartis ... not be able to conduct// their drug research here in ... its research now. ,While talking ... of Novartis reveals that this decision by the Indian government ...
Cached Medicine News:Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3Health News:Researchers Make Strides in VCJD Detection 2Health News:NIMH Studies Woman’s Hormonal Cycl 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2
... CELL-DYN are assayed linearity control kits that ... verify patient reportable range of three- and ... the linear performance of the analyzer. CVA ... ranges appropriate for each instrument model and ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
... Proprietary EX.P.R.T. Release Technology essentially ... stent shortening,, Unique anatomically designed tapered ... carotid bifurcation,, 0.014 Rapid Exchange catheter ... and flexible atraumatic tip,, Radiopaque marker ...
... Para 5X is a whole blood hematology ... 60C+, 80 and 120, and the Coulter ... offers a unique white cell differential, positioning ... algorithms on the systems. The product offers ...
Medicine Products: